Trial Profile
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies, Followed by an Expansion in Subjects With Measurable Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sapanisertib (Primary)
- Indications Adenocarcinoma; Bladder cancer; Endometrial cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 19 Feb 2019 Status changed from active, no longer recruiting to completed.
- 07 Jan 2019 Planned End Date changed from 31 Oct 2018 to 31 Jan 2019.
- 24 Aug 2018 Planned End Date changed from 30 Jun 2018 to 31 Oct 2018.